# Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

> **NCT02615054** · — · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Trastuzumab Cardiotoxicity
- HER2-Positive Breast Cancer Survivors

## Interventions

- **DEVICE:** 2D Echocardiogram
- **DEVICE:** Cardiopulmonary exercise testing and post-CPET cardiac function

## Key facts

- **NCT ID:** NCT02615054
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-18
- **Primary completion:** 2024-03-05
- **Final completion:** 2024-03-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615054, "Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02615054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*